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OBJECTIVE— Despite widespread dissemination of target values, achieving a blood pres-
sure of 130/80 mmHg is challenging for many individuals with diabetes. The purpose of the
present study was to examine temporal trends in blood pressure control in hypertensive indi-
viduals with diabetes as well as the potential for race, sex, and geographic disparities.
RESEARCHDESIGNANDMETHODS— We analyzed baseline data from the REasons
for Geographic And Racial Differences in Stroke (REGARDS) study, a national, population-
based, longitudinal cohort study of 30,228 adults (58% European American and 42% African
American), examining the causes of excess stroke mortality in the southeastern U.S. We calcu-
lated mean blood pressure and blood pressure control rates (proportion with blood pressure
130/80 mmHg) for 5,217 hypertensive diabetic participants by year of enrollment (2003–
2007) using multivariable logistic regression models.
RESULTS— Only 43 and 30% of European American and African American diabetic hyper-
tensive participants, respectively, demonstrated a target blood pressure of130/80 mmHg (P
0.001). However, a temporal trend of improved control was evident; the odds of having a blood
pressure 130/80 mmHg among diabetic hypertensive participants of both races enrolled in
2007 (as compared with those enrolled in 2003) were50% greater (P 0.001) in multivariate
models.
CONCLUSIONS— These data suggest temporal improvements in blood pressure control in
diabetes that may reflect broad dissemination of tighter blood pressure control targets and
improving medication access. However, control rates remain low, and significant racial dispar-
ities persist among African Americans that may contribute to an increased risk for premature
cardiovascular disease.
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In 2003, the Joint National Committee(JNC) on Prevention, Detection, Eval-uation, and Treatment of High Blood
Pressure published (1) revised recom-
mendations (JNC 7) on the management
of hypertension that recommended a
lower target for patients with diabetes
(130/80 mmHg) than for the general pop-
ulation with uncomplicated essential hy-
pertension (140/90 mmHg). This
differential target was originally based on
early studies (2,3), suggesting a benefit
from further blood pressure reduction in
helping to offset higher renal and cardio-
vascular risk. Subsequent evidence from
the UK Prospective Diabetes Study
(UKPDS) (4), the Hypertension Optimal
Treatment (HOT) (5) Study, the Action in
Diabetes and Vascular Disease: Preterax
and Diamicron MR Controlled Evaluation
(ADVANCE) (6) Study, and the Stop Ath-
erosclerosis in Native Diabetics Study
(SANDS) (7) all demonstrated improved
outcomes in patients assigned to tighter
blood pressure control. The Action to
Control Cardiovascular Risk in Diabetes
(ACCORD) (8) Study, despite discontin-
uation of an intensive glucose reduction
arm in February 2008 (9), is investigating
the value of reducing blood pressure to
120 mmHg, and results will be available
soon.
Published goal values for blood pres-
sure in patients with diabetes of 130
mmHg for systolic blood pressure and
80 mmHg for diastolic blood pressure
represent a differential and more aggres-
sive target for diabetic patients when
compared with uncomplicated nondia-
betic patients with essential hypertension.
However, the extent to which this differ-
ential goal has been effectively achieved in
routine practice has not been sufficiently
examined, especially in large national
samples. Wang (10) examined the effect
of this guideline change on hypertension
control in diabetic patients during the
time period 1995 through 2005 and dem-
onstrated only a modest differential im-
provement in blood pressure control in
diabetic subjects. However, this physician
office–based study was insufficient to ex-
amine the population-level impact of the
2003 JNC 7 guideline change. Popula-
tion-level data from National Health and
Nutrition Examination Survey 1999
through 2004 (11) suggest more substan-
tial improvement in blood pressure con-
trol in patients with diabetes; however,
the timing of these observations does not
allow examination of the longitudinal ef-
fects of the 2003 guideline change. Addi-
t iona l l y , inves t i ga to r s have not
sufficiently examined the potential for ra-
cial and geographic differences in the ex-
tent to which blood pressure control has
improved in a population-based sample
in response to these guideline changes.
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Because of differential risks for diabetic
complications by race, such studies are of
critical importance. Therefore, the pur-
pose of the present study is to examine
temporal trends in blood pressure control
in hypertensive individuals with diabetes
as well as the potential for race, sex, and
geographic disparities. To meet these
goals, the primary analysis herein is to
compare mean systolic and diastolic
blood pressure values and the proportion
of hypertensive diabetic subjects with
guideline-recommended blood pressure
values by race, sex, and region across dif-
ferent time points over the time period
2003 through 2007.
RESEARCH DESIGN AND
METHODS— The REasons for Geo-
graphic And Racial Disparities in Stroke
(REGARDS) study is a study of health dis-
parities and stroke incidence, the meth-
ods of which have been described in detail
elsewhere (12). In short, the study is a
population-based, longitudinal cohort
study of 30,228 subjects aged45 years,
55% of whom are male, 45% female, 42%
African American, 58% European Ameri-
can, 56% from stroke belt regions, and
44% from the rest of the country. The
study was designed to examine the causes
of excess stroke mortality in the south-
eastern U.S. and among African Ameri-
cans, relative to the rest of the nation.
Because of the large size of this study, its
national scope, its enrollment of the co-
hort during the implementation of new
guidelines for blood pressure control in
diabetic subjects, and the inclusion of
large numbers of adults with diabetes,
many of whom also have hypertension,
this study provides a unique opportunity
to examine recent trends in blood pres-
sure control among African American and
European American hypertensive adults
with diabetes using baseline data assem-
bled across 5 years in the REGARDS
study.
The study included a detailed com-
puter-assisted telephone interview with
each adult subject to collect demographic
characteristics, including age, race (each
subject self-reported race; this study com-
pared only African American and Euro-
pean American subjects), sex, annual
household income ($20,000/year,
$20,000 –$35,000/year, $35,000 –
$75,000/year, and$75,000/year), edu-
cation level (less than high school
education, high school graduate, some
college, and college graduate or higher),
health insurance, health behaviors such
as smoking (categorized as nonsmoker,
past smoker, or current smoker), exercise
(how often per week they exercised
enough to work up a sweat; categorized as
never, one to three times per week, or four
or more times per week), alcohol con-
sumption (categorized as nondrinker,
one to seven drinks per week, and seven
or more drinks per week), and medical
history information.
Following the telephone interview,
each subject was evaluated by a trained
health professional who conducted an in-
home assessment that included measure-
ment of height and weight via standard
procedures, after which BMI was calcu-
lated as the weight in kilograms divided
by the square of height in meters. Blood
pressure was obtained with an aneroid
sphygmomanometer, using the appropri-
ate cuff size and measured after being in
the seated position with both feet on the
floor for at least 3 min. Blood pressure
measurement was repeated twice, and the
average value was used in these analyses.
At the home visit, blood specimens were
obtained and total and HDL cholesterol
were measured in accordance with the
National Cholesterol Education Program
guidelines (13). All medications were
carefully recorded at the home visit, and
self-reported medication adherence/
nonadherence was assessed based on a
validated scale (14).
For the present study, all subjects
were identified who reported in their tele-
phone interview that a physician had told
them that they had both hypertension/
high blood pressure and diabetes, as well
as those who reported having hyperten-
sion and who had a fasting blood glucose
125 mg/dl measured during the home
visit. Excluded from these analyses were
any subjects who failed to respond to ei-
ther the question on self-reported hyper-
tension or self-reported diabetes (n 32)
and those without self-reported hyper-
tension (n 12,774), resulting in an anal-
ysis cohort of 5,217 subjects. The study
was approved by the institutional review
board, and each subject provided in-
formed consent.
The primary analysis was to compare
mean systolic and diastolic blood pres-
sure values (obtained during the home
visit) and the proportion of subjects meet-
ing guideline-recommended blood pres-
sure goals (130/80 mmHg), by race,
among hypertensive subjects with diabe-
tes enrolled at different time points over
the time period 2003 through 2007. The
mean blood pressure values were com-
pared between races and across time us-
ing a general linear model that adjusted
for age, sex, region (categorized as stroke
belt, stroke buckle, rest of the nation), ex-
ercise, income, education, smoking, total
and HDL cholesterol, and the number of
antihypertensive medications. Hyperten-
sive diabetic subjects were also compared
by race with respect to the proportion of
subjects whose blood pressure was
130/80 mmHg, examined first in an un-
adjusted (crude) logistic regression model
and in additional models that progres-
sively adjusted for 1) demographic char-
acteristics (race, age and sex, and region)
and year of enrollment, 2) after further
adjustment for risk factors related to both
hypertension and diabetes (BMI and ex-
ercise), 3) after further adjustment for fac-
tors related to access to care and the
potential for blood pressure control (in-
come, education, insurance, medication
use, and self-reported medication nonad-
herence), and finally 4) after adjustment
for levels of cardiovascular risk by the in-
troduction of additional cardiovascular
risk factors (smoking and total and HDL
cholesterol). All analyses were performed
using SAS version 9 (SAS, Cary, NC).
RESULTS— This study included 5,217
subjects who reported having both hyper-
tension and diabetes. Details regarding
the study population are given in Table 1.
The majority of the European Americans
with hypertension and diabetes were
male, while the majority of African Amer-
icans with hypertension and diabetes
were female. As detailed in Table 2, mean
blood pressure in European American di-
abetic hypertensive subjects was signi-
ficantly lower than that in African Amer-
ican diabetic hypertensive subjects
(130  16/75  10 mmHg vs. 135 
17/78  10 mmHg) (P  0.001). While
the majority of subjects in both races were
not at a target blood pressure value of
130/80 mmHg, significantly more Eu-
ropean American than African American
diabetic hypertensive subjects were at or
below this threshold (43 vs. 30%, respec-
tively; P  0.001). In multivariate-
adjusted models, the odds of African
American subjects being below this target
value were 39% lower than the odds of
European American subjects (Table 3).
Further, in multivariate-adjusted models,
the odds of being below this target value
were 66% higher in women than men.
Self-reported medication adherence was
not significantly different by race, sex, or
year of enrollment; however, older age
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was associated with modestly lower med-
ication adherence that was independent
of education and income level. There was
no clear pattern of correlates in multiva-
riate-adjusted models that might explain
the racial differences in blood pressure
control. There were also no significant
geographic trends in multivariate models;
hypertensive diabetic subjects from the
southeastern U.S. had blood pressure
control rates that did not differ from those
observed in subjects from across the
country after other factors were con-
trolled for.
Most compelling, however, were the
differences observed across the time pe-
riod of enrollment. There was a significant
trend for those enrolled in later years to
have better blood pressure control. Mean
systolic blood pressure for hypertensive
diabetic African Americans enrolled in
2003 was 135.5 mmHg, while mean sys-
tolic blood pressure for those enrolled in
2007 was 130.7 mmHg. Similarly, mean
systolic blood pressure for hypertensive
diabetic European Americans enrolled in
2003 was 131.6 mmHg, while mean sys-
tolic blood pressure for those enrolled in
2007 was 125.9 mmHg. When examined
in multivariate-adjusted models that pro-
gressively adjusted for demographics,
BMI, exercise, income, education, insur-
ance, self-reported medication adher-
ence, smoking, total cholesterol, and HDL
cholesterol, the odds of achieving a blood
pressure 130/80 mmHg among those
enrolled in 2007 were 50% higher than
among those subjects enrolled in 2003,
regardless of race (P  0.0008 for trend)
(Fig. 1). There was no significant race 
time interaction observed across this time
period, suggesting that improvements
over time did not differ by race.
CONCLUSIONS— This nationwide
study of blood pressure control in African
American and European American hyper-
tensive diabetic subjects demonstrates
that less than half of the subjects in both
racial groups had a measured blood pres-
sure less than the target of 130/80 mmHg
recommended by the American Diabetes
Association and in JNC 7, that race and
sex disparities in blood pressure control
continue to exist, but that between 2003
and 2007 there has been improved blood
pressure control in both racial groups.
The need for careful blood pressure con-
trol in hypertensive diabetic subjects is
underscored by the fact that blood pres-
sure control is one of the most important
determinants of cardiovascular risk
(4,15,16); it is the subject of numerous
investigations, including current studies
to investigate the magnitude of blood
pressure lowering (6–9), and it is a major
component of published guidelines on
patient management that have been
widely promulgated (1,17). Our data
showed that income, education, insur-
ance, and medication adherence were not
independently associated with inade-
quate blood pressure control when other
variables were controlled for, suggesting
that other factors may be influencing this
outcome. The potential reasons for inad-
equate blood pressure control are nu-
merous and include not only patient
knowledge but also biological resistance,
patient lifestyle/behavioral choices, co-
morbid conditions and treatments, med-
ication nonadherence, and health system
factors, including limited access to care,
discrimination by race and sex, compet-
ing demands of providers, lack of knowl-
edge or adoption of the guideline, and the
lack of treatment intensification. These
and other factors have been recently de-
scribed in the study by Bosworth et al.
(18).
Table 1—Demographic and cardiovascular risk characteristics by race of the REGARDS study
population with hypertension and diabetes (n  5,217)
European American African American
n 2,054 3,163
Mean age (years) 67.2  8.4 65.7  8.6
Sex (% female) 43.2 62.1
Stroke belt resident (%) 64.1 54.1
Less than high school education (%) 11.4 26.9
High school graduate (%) 29.0 29.0
Some college (%) 29.6 23.9
College graduate (%) 30.0 20.2
Health insurance (%) 95.6 91.4
Household annual income (%)
$20,000 20.8 37.9
$20,000–$35,000 30.1 32.1
$35,000–$75,000 35.4 23.2
$75,000 13.7 6.9
Proportion on antihypertensive medication
reporting any nonadherence (%) 35.5 34.2
Current smoker (%) 11.7 15.2
Weekly exercise (%)
None 43.2 43.1
One to three times 30.4 34.7
Four or more times 26.5 22.3
Alcohol use (%)
None 5.7 2.2
Less than one drink per day 35.2 28.7
More than one drink per day 59.1 69.1
Mean BMI 32  6 33  7
Mean total cholesterol (mg/dl) 176  41 181  42
Mean HDL cholesterol (mg/dl) 43  13 50  15
Data are means  SD unless otherwise indicated.
Table 2—Mean systolic and diastolic pressure values in diabetic hypertensive subjects and
proportion meeting guideline targets by race
European American African American
n 2,054 3,163
Systolic blood pressure 130  16 135  17*
Diastolic blood pressure 75  10 78  10*
Percent meeting American Diabetes
Association guidelines (130/80 mmHg) 43% 30%
Data are means  SD unless otherwise indicated. *P  0.01.
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Data from the REGARDS study re-
ported previously by Safford et al. (19)
demonstrated that African American hy-
pertensive subjects were more likely to
have a more intense antihypertensive reg-
imen than European Americans across all
age and income strata but still were more
likely to have elevated blood pressure val-
ues. This suggests treatment resistance
and/or medication nonadherence. How-
ever, our findings demonstrated no racial
differences in self-reported medication
adherence. These findings are in contrast
to those of Bosworth et al. (20), who
found that African Americans in the Vet-
erans Administration system were 81%
more likely than European Americans to
be nonadherent with medications for
blood pressure control. However, the
findings of Bosworth et al. were not lim-
ited to diabetic subjects. The fact that a
smaller proportion of male than female
diabetic hypertensive subjects had a mea-
sured blood pressure that was less than
published target values may contribute to
sex differences in premature mortality in
this high-risk population.
Most significant, however, was the im-
provement between 2003 and 2007 in the
proportion of diabetic hypertensive enroll-
ees in both races who met target blood pres-
sure control values. These gains were
substantial and clinically important for both
African Americans and European Ameri-
cans. This trend has important national
public health implications with respect to
reducing cardiovascular risk in this high-
risk population. The reason for this trend of
improved blood pressure control is not
clear but may relate to improved dissemina-
tion or adoption of more stringent blood
pressure control target values, improved
Figure 1—Odds of hypertension control among hypertensive diabetic participants. Odds ratio
and 95% CIs; n  4,054; 2003 reference year. Adjusted for race, sex, age, region, BMI, weekly
exercise income, education, insurance, availability, adherence to treatment, smoking, total cho-
lesterol, and HDL.
Table 3—Correlates of blood pressure <130/80 mmHg among hypertensive diabetic patients from multivariate model
Demographic Fitness
Socioeconomic
status CV risk factor
n 5,214 5,064 4,299 4,054
Race 0.55 (0.49–0.62) 0.55 (0.48–0.62) 0.59 (0.51–0.68) 0.61 (0.52–0.70)
Female sex 1.27 (1.12–1.43) 1.38 (1.22–1.57) 1.45 (1.26–1.67) 1.66 (1.42–1.94)
Age (10-year difference) 1.06 (0.99–1.14) 1.00 (0.93–1.07) 0.99 (0.91–1.08) 0.97 (0.88–1.05)
2004 (relative to 2003) 0.99 (0.83–1.18) 0.99 (0.82–1.19) 1.04 (0.86–1.27) 1.01 (0.82–1.23)
2005 (relative to 2003) 1.24 (1.02–1.50) 1.23 (1.01–1.50) 1.15 (0.93–1.42) 1.08 (0.87–1.35)
2006 (relative to 2003) 1.24 (1.01–1.53) 1.28 (1.03–1.58) 1.20 (0.95–1.51) 1.11 (0.88–1.35)
2007 (relative to 2003) 1.62 (1.31–2.00) 1.64 (1.32–2.03) 1.62 (1.28–2.05) 1.50 (1.18–1.92)
Stroke belt region 0.98 (0.87–1.11) 0.97 (0.86–1.10) 1.02 (0.89–1.17) 1.04 (0.90–1.20)
BMI 0.97 (0.96–0.98) 0.97 (0.96–0.98) 0.97 (0.96–0.98)
Exercise one to three times per week (relative to none) 0.95 (0.82–1.09) 0.92 (0.79–1.06) 0.90 (0.77–1.05)
Exercise four or more times per week (relative to none) 1.02 (0.88–1.19) 1.00 (0.85–1.18) 0.99 (0.83–1.17)
Income $20,000–$35,000 (relative to $20,000) 1.07 (0.90–1.28) 1.08 (0.90–1.29)
Income $35,000– $75,000 (relative to $20,000) 1.36 (1.12–1.65) 1.38 (1.13–1.69)
Income $75,000 (relative to $20,000) 1.27 (0.96–1.66) 1.30 (0.98–1.72)
Education high school graduate (relative to less than
high school graduate) 1.15 (0.94–1.41) 1.19 (0.96–1.46)
Education some college (relative to less than high
school graduate) 1.20 (0.97–1.48) 1.20 (0.97–1.50)
Education college graduate (relative to less than high
school graduate) 1.08 (0.86–1.35) 1.09 (0.86–1.38)
Insurance 0.74 (0.56–0.98) 0.80 (0.60–1.07)
Medication adherence 1.08 (0.94–1.24) 1.07 (0.93–1.23)
Current smoking 0.92 (0.75–1.12)
Total cholesterol (10 mg/dl) 0.95 (0.93–0.97)
HDL (10 mg/dl) 0.95 (0.90–1.00)
Data are odds ratio (95% CI) unless otherwise indicated.
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patient-specific self-management and/or
lifestyle choices, improved treatment inten-
sification, improved access to medical care,
and/or improved access to antihypertensive
medications as a result of the national im-
plementation of Medicare Part D coverage
and generic reduced out-of-pocket cost
(WalMart-type) formularies (21). These lat-
ter factors may be particularly important,
considering that the largest improvement in
the proportion of subjects with adequate
blood pressure control occurred between
2006 and 2007 following the implementa-
tion of both Medicare Part D insurance and
WalMart’s reduced-cost formulary, both in
2006.
The present study has limitations, in-
cluding its cross-sectional design, the use of
self-reported disease and medication adher-
ence measures, and the lack of data on pro-
teinuria. Specifically, it is possible that for
reasons we do not understand, hyperten-
sive diabetic individuals recruited to the
study during the latter years were more
likely to have improved blood pressure con-
trol. The REGARDS study did adjust its
sampling rates to meet race and sex recruit-
ment goals; however, these analyses were
stratified by race and controlled for sex,
and, as such, race would not have played a
role in any results and sex would not have
played a role in the multivariable results. In
addition, we attempted to adjust for other
factors that could have changed over the
study period (adherence, access to health
insurance, etc.), and these factors failed to
mediate the observed temporal improve-
ment in control. Nevertheless, it is possible
that factors that we did not account for in
the analysis could have changed over time
and confounded our results. However,
these potential weaknesses are offset by the
large and representative nature of this na-
tional population-based study and by the
measurement of blood pressure in the home
by a trained professional using a standard-
ized protocol.
These data suggest substantial national
improvements in blood pressure control in
individuals with concurrent hypertension
and diabetes, similar to that reported by Mc-
Williams et al. (22). The etiology of these
improvements is unknown, but they may
reflect the broad dissemination of tighter
blood pressure control targets and improv-
ing medication access. However, despite
temporal trends suggesting improvement,
significant racial disparities in successful
blood pressure control persist among Afri-
can Americans and may contribute to the
increased risk for premature cardiovascular
disease and stroke in this population. Addi-
tional interventions to facilitate the achieve-
ment of goal blood pressure values in all
hypertensive diabetic subjects appear
warranted.
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